search
Back to results

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
France
Study Type
Interventional
Intervention
Placebo
BIA 5-453
Sponsored by
Bial - Portela C S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. A signed and dated informed consent form before any study-specific screening procedure is performed.
  2. Male patients aged between 18 and 65 years (inclusive)
  3. Body mass index (BMI) between 18 and 35 kg/m2 (inclusive)
  4. Patients with essential hypertension, without previous treatment (but in which treatment was justified), defined at the selection visit as blood pressure (BP) after 10 minutes of rest in supine position of

    • diastolic blood pressure (DBP) ≥ 90 mmHg and/or,
    • systolic blood pressure (SBP) ≥ 140 mmHg
  5. Patients with essential hypertension, with previous treatment, defined at the end of the screening period (i.e. after 3 weeks wash-out of antihypertensive treatment(s) and before D-1) as blood pressure (BP) after 10 minutes of rest in supine position of

    • diastolic blood pressure (DBP) ≥ 90 mmHg and/or,
    • systolic blood pressure (SBP) ≥ 140 mmHg
  6. Naive or patients taking any class of antihypertensive treatment including (but not limited to) one of the following authorised treatments: B-blockers, diuretics, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), calcium channel blockers. Patients observed a wash-out for their antihypertensive treatments of approximately 3 weeks.
  7. Laboratory tests within the normal range of the laboratory (haematology, biochemistry and urinalysis) or considered as not clinically significant by the investigator.
  8. Electrocardiogram recording on a 12-lead ECG without any clinically significant abnormality
  9. Covered by National Health Insurance
  10. Once clinical eligibility had been established, patients conducted 24 h ambulatory blood pressure monitoring (ABPM) at the end of the screening period, and after treatment wash-out for patients already treated. They had to meet the following off-treatment criteria for mean 24 h ambulatory blood pressure measurements to be included in the study:

    • Average daytime ambulatory systolic/diastolic BP ≥ 135 / 85 mm Hg and/or
    • Ambulatory night-time systolic/diastolic BP ≥ 120 / 70 mm Hg.

Exclusion Criteria:

Criteria associated with hypertension, associated risk factors, and target organ damage:

  1. Severe hypertension (SBP≥180 mm Hg and/or DBP≥110 mm Hg) at any time during the study from screening period to end of study visit or in the medical history, malignant hypertension
  2. Secondary hypertension (including known renovascular hypertension, pheochromocytoma)
  3. Any recent history of coronary artery disease (in the previous 6 months) and including myocardial infarction, or precordial pain suggesting angina pectoris and coronary revascularisation
  4. Any recent history of cardiac failure (in the previous 6 months)
  5. Any recent history of cerebrovascular stroke or transient ischemia (in the previous 6 months)
  6. Any known aortic or mitral valve stenosis or hypertrophic obstructive myocardiopathy
  7. Any known severe ocular complication of hypertension (stage III or IV retinopathy),
  8. Any history of ventricular rhythm disorders (torsades de pointes, ventricular tachycardia, polymorphic ventricular extra-systoles except isolated extra-systoles), auricular disorders (fibrillation or flutter).
  9. Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of Etamicastat (BIA 5-453)
  10. Presence or history of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological or psychiatric disease.
  11. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).

    Criteria associated with patient characteristic:

  12. History or presence of drug dependence.
  13. Patients smoking more than 10 cigarettes per day
  14. History of alcoholism within 1 year before day 1. Consumption of more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g
  15. Participation in a drug trial within 3 months preceding the selection visit.
  16. Positive result from the hepatitis serology for hepatitis B (HBs Ag) and/or hepatitis C (HCV Ab).
  17. Positive result for HIV1+2 serology.
  18. Positive Urine Drug Screen (UDS) (amphetamines, benzodiazepines, ecstasy, cocaine, opiates).
  19. Loss of greater than 400 mL or blood donation within the last 3 months.

    Criteria associated with concomitant diseases:

  20. Patients taking one of the following treatments: aldosterone antagonists, nitrite derivatives.
  21. Presence or history of any allergic or unusual reaction to drugs.
  22. Excessive consumption of beverages containing xanthine bases (more than six cups or glasses per day) or inability to stop consumption during the hospitalization.

Sites / Locations

  • Biotrial

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Group 1 - BIA 5-453 50 mg or placebo

Group 2 - BIA 5-453 100 mg or placebo

Group 3 - BIA 5-453 200 mg or placebo

Arm Description

This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions. On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration. On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast. The patients were administered between 7:00 and 9:00 o'clock a.m

This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions. On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration. On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast. The patients were administered between 7:00 and 9:00 o'clock a.m

This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions. On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration. On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast. The patients were administered between 7:00 and 9:00 o'clock a.m

Outcomes

Primary Outcome Measures

Cmax: Maximum observed plasma concentration (Plasma results on Day 1)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
tmax: time to reach maximum plasma concentration (Plasma results on Day 1)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AUC0-t: Area under the plasma concentration-time curve from time zero to last measurable plasma concentration (Plasma results on Day 1)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AUC0-24: AUC from time zero to 24h-post dose (Plasma results on Day 1)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Cmax: Maximum observed plasma concentration (Plasma results on Day 10)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
tmax: time to reach maximum plasma concentration (Plasma results on Day 10)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AUC0-t: Area under the plasma concentration-time curve from time zero to last measurable plasma concentration (Plasma results on Day 10)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AUC0-24: AUC from time zero to 24h-post dose (Plasma results on Day 10)
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
C max : Maximum excretion rate (Urine results on Day 1)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
tmax : Time of Maximum Excretion Rate (Urine results on Day 1)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AURC(0-tlast) : Area Under the Urine Excretion Curve from time zero to last time (Urine results on Day 1)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AmtCUM : Cumulative Amount of Drug excreted in urine (Urine results on Day 1)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
C max : Maximum excretion rate (Urine results on Day 10)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
tmax : Time of Maximum Excretion Rate (Urine results on Day 10)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AURC(0-tlast) : Area Under the Urine Excretion Curve from time zero to last time (Urine results on Day 10)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
AmtCUM : Cumulative Amount of Drug excreted in urine (Urine results on Day 10)
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects

Secondary Outcome Measures

Full Information

First Posted
March 28, 2017
Last Updated
March 31, 2017
Sponsor
Bial - Portela C S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT03099226
Brief Title
Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453
Official Title
A Double-blind, Randomised, Placebo-controlled Study to Evaluate the Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of Etamicastat (BIA 5-453) in Hypertensive Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
March 2017
Overall Recruitment Status
Completed
Study Start Date
July 15, 2008 (Actual)
Primary Completion Date
April 3, 2009 (Actual)
Study Completion Date
April 3, 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bial - Portela C S.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study was to characterise the plasma and urine pharmacokinetic profile of Etamicastat (BIA 5-453) and its metabolites after three multiple rising dose regimens of Etamicastat (BIA 5-453).
Detailed Description
Single centre, double-blind, randomised, placebo-controlled study of three dosage regimens of Etamicastat (BIA 5-453) in 3 groups of 8 hypertensive patients. In each group, the study consisted of a 10-day multiple-dose period. Progression to the next dose level only occurred if the previous dose level was considered to be safe and well tolerated. An appropriate interval separated the investigation of doses to permit a timely review and evaluation of safety data prior to proceeding to a higher dose level.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
23 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Group 1 - BIA 5-453 50 mg or placebo
Arm Type
Experimental
Arm Description
This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions. On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration. On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast. The patients were administered between 7:00 and 9:00 o'clock a.m
Arm Title
Group 2 - BIA 5-453 100 mg or placebo
Arm Type
Experimental
Arm Description
This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions. On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration. On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast. The patients were administered between 7:00 and 9:00 o'clock a.m
Arm Title
Group 3 - BIA 5-453 200 mg or placebo
Arm Type
Experimental
Arm Description
This study investigated the doses of 50, 100 and 200 mg of Etamicastat (BIA 5-453) during 10 days administered q.d. in the morning under fasting conditions. On Day 1 and Day 10, patients remained fasted from a minimum of 8 hours before drug administration until after the collection of the 4 hour PK timepoint. Individuals were served a meal following the 4 hour timepoint and had free access to a maximum of 2.5 litres of water per day. However they were not allowed to drink 1 hour before and 1 hour after the dosing except for the 250 mL taken with the IMP at administration. On other administrations days, patients remained fasted for a minimum of 8 hours before drug administration and the treatments were administered one hour before a standardized breakfast. The patients were administered between 7:00 and 9:00 o'clock a.m
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo blue hard gelatine capsules
Intervention Type
Drug
Intervention Name(s)
BIA 5-453
Other Intervention Name(s)
Etamicastat
Intervention Description
Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
Primary Outcome Measure Information:
Title
Cmax: Maximum observed plasma concentration (Plasma results on Day 1)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and H0.5 , 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 post-dose
Title
tmax: time to reach maximum plasma concentration (Plasma results on Day 1)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and H0.5 , 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 post-dose
Title
AUC0-t: Area under the plasma concentration-time curve from time zero to last measurable plasma concentration (Plasma results on Day 1)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and H0.5 , 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 post-dose
Title
AUC0-24: AUC from time zero to 24h-post dose (Plasma results on Day 1)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and H0.5 , 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 post-dose
Title
Cmax: Maximum observed plasma concentration (Plasma results on Day 10)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and H0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,16, 24, 48 and 72 h post-dose
Title
tmax: time to reach maximum plasma concentration (Plasma results on Day 10)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and H0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,16, 24, 48 and 72 h post-dose
Title
AUC0-t: Area under the plasma concentration-time curve from time zero to last measurable plasma concentration (Plasma results on Day 10)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and H0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,16, 24, 48 and 72 h post-dose
Title
AUC0-24: AUC from time zero to 24h-post dose (Plasma results on Day 10)
Description
Plasma pharmacokinetic parameters (SD) following single and repeated doses of 50, 100, and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and H0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,16, 24, 48 and 72 h post-dose
Title
C max : Maximum excretion rate (Urine results on Day 1)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and 0-4, 4-8, 8-12, 12-24 h post-dose
Title
tmax : Time of Maximum Excretion Rate (Urine results on Day 1)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and 0-4, 4-8, 8-12, 12-24 h post-dose
Title
AURC(0-tlast) : Area Under the Urine Excretion Curve from time zero to last time (Urine results on Day 1)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and 0-4, 4-8, 8-12, 12-24 h post-dose
Title
AmtCUM : Cumulative Amount of Drug excreted in urine (Urine results on Day 1)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D1 pre-dose, and 0-4, 4-8, 8-12, 12-24 h post-dose
Title
C max : Maximum excretion rate (Urine results on Day 10)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and 0-4, 4-8, 8-12, 12-24, 24-48, 48 72 h post-dose
Title
tmax : Time of Maximum Excretion Rate (Urine results on Day 10)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and 0-4, 4-8, 8-12, 12-24, 24-48, 48 72 h post-dose
Title
AURC(0-tlast) : Area Under the Urine Excretion Curve from time zero to last time (Urine results on Day 10)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and 0-4, 4-8, 8-12, 12-24, 24-48, 48 72 h post-dose
Title
AmtCUM : Cumulative Amount of Drug excreted in urine (Urine results on Day 10)
Description
Urine pharmacokinetic parameters (SD) following single and repeated doses of 100 and 200 mg of Etamicastat (BIA 5-453) in hypertensive subjects
Time Frame
D10 pre-dose, and 0-4, 4-8, 8-12, 12-24, 24-48, 48 72 h post-dose

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A signed and dated informed consent form before any study-specific screening procedure is performed. Male patients aged between 18 and 65 years (inclusive) Body mass index (BMI) between 18 and 35 kg/m2 (inclusive) Patients with essential hypertension, without previous treatment (but in which treatment was justified), defined at the selection visit as blood pressure (BP) after 10 minutes of rest in supine position of diastolic blood pressure (DBP) ≥ 90 mmHg and/or, systolic blood pressure (SBP) ≥ 140 mmHg Patients with essential hypertension, with previous treatment, defined at the end of the screening period (i.e. after 3 weeks wash-out of antihypertensive treatment(s) and before D-1) as blood pressure (BP) after 10 minutes of rest in supine position of diastolic blood pressure (DBP) ≥ 90 mmHg and/or, systolic blood pressure (SBP) ≥ 140 mmHg Naive or patients taking any class of antihypertensive treatment including (but not limited to) one of the following authorised treatments: B-blockers, diuretics, angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), calcium channel blockers. Patients observed a wash-out for their antihypertensive treatments of approximately 3 weeks. Laboratory tests within the normal range of the laboratory (haematology, biochemistry and urinalysis) or considered as not clinically significant by the investigator. Electrocardiogram recording on a 12-lead ECG without any clinically significant abnormality Covered by National Health Insurance Once clinical eligibility had been established, patients conducted 24 h ambulatory blood pressure monitoring (ABPM) at the end of the screening period, and after treatment wash-out for patients already treated. They had to meet the following off-treatment criteria for mean 24 h ambulatory blood pressure measurements to be included in the study: Average daytime ambulatory systolic/diastolic BP ≥ 135 / 85 mm Hg and/or Ambulatory night-time systolic/diastolic BP ≥ 120 / 70 mm Hg. Exclusion Criteria: Criteria associated with hypertension, associated risk factors, and target organ damage: Severe hypertension (SBP≥180 mm Hg and/or DBP≥110 mm Hg) at any time during the study from screening period to end of study visit or in the medical history, malignant hypertension Secondary hypertension (including known renovascular hypertension, pheochromocytoma) Any recent history of coronary artery disease (in the previous 6 months) and including myocardial infarction, or precordial pain suggesting angina pectoris and coronary revascularisation Any recent history of cardiac failure (in the previous 6 months) Any recent history of cerebrovascular stroke or transient ischemia (in the previous 6 months) Any known aortic or mitral valve stenosis or hypertrophic obstructive myocardiopathy Any known severe ocular complication of hypertension (stage III or IV retinopathy), Any history of ventricular rhythm disorders (torsades de pointes, ventricular tachycardia, polymorphic ventricular extra-systoles except isolated extra-systoles), auricular disorders (fibrillation or flutter). Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism, or excretion of Etamicastat (BIA 5-453) Presence or history of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, haematological, neurological or psychiatric disease. Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month). Criteria associated with patient characteristic: History or presence of drug dependence. Patients smoking more than 10 cigarettes per day History of alcoholism within 1 year before day 1. Consumption of more than 50 g of ethanol per day (12.5 cL glass of 10° [10%] wine = 12 g; 4 cL of aperitif, 42° [42%] whiskey = 17 g; 25 cL glass of 3° [3%] beer = 7.5 g; 25 cL glass of 6° [6%] beer = 15 g Participation in a drug trial within 3 months preceding the selection visit. Positive result from the hepatitis serology for hepatitis B (HBs Ag) and/or hepatitis C (HCV Ab). Positive result for HIV1+2 serology. Positive Urine Drug Screen (UDS) (amphetamines, benzodiazepines, ecstasy, cocaine, opiates). Loss of greater than 400 mL or blood donation within the last 3 months. Criteria associated with concomitant diseases: Patients taking one of the following treatments: aldosterone antagonists, nitrite derivatives. Presence or history of any allergic or unusual reaction to drugs. Excessive consumption of beverages containing xanthine bases (more than six cups or glasses per day) or inability to stop consumption during the hospitalization.
Facility Information:
Facility Name
Biotrial
City
Rennes
ZIP/Postal Code
F-35000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Dose Regimens of BIA 5-453

We'll reach out to this number within 24 hrs